Data from the phase one safety trial of the vaccine showed only mild adverse effects, and generated an immune response in volunteers aged 18 to 71, Dr. Jacqueline Miller, therapeutic area head for infectious diseases at Moderna, told a meeting of the Advisory Committee on Immunization Practices.
The phase one trial was conducted in three age groups: 18 to 55, 56 to 70 and 71 plus years of age. Participants received two 100mg doses of the vaccine 28 days apart.
Neutralizing antibodies – which inactivate the virus — were detected in all participants, including the upper age range, she told the meeting. All age groups also seemed to produce the same immune response – a good sign, as older people often have weaker responses to vaccines.
The most common adverse reactions were fatigue, chills, headache and myalgia. More reports of adverse symptoms observed after the second dose of the vaccine, but the majority of symptoms resolved within two days.
ACIP advises the Centers for Disease Control and Prevention on how vaccines should be used in the population.